As of 12:30 PM on October 28, Green Cross is trading at 265,500 KRW, up 3.71% from the previous day. The trading volume stands at 348,665 shares, which is 97.98% of the previous day's trading volume. Green Cross is known as a pharmaceutical company specializing in blood products and vaccines.
On October 23, Lee Hyerin, a researcher at KTB Investment & Securities, stated, "The CMO agreement for COVID-19 vaccines with CEPI (Coalition for Epidemic Preparedness Innovations) is a surprise development. We expect the company to sign additional concrete CMO contracts with multiple global pharmaceutical companies in the future. While it is difficult to guarantee the long-term sustainability of the COVID-19 vaccine business, it is expected to serve as a cash cow in the short to medium term." She set the target price for Green Cross at 300,000 KRW.
Over the past five days, individual investors have recorded a net selling of 214,402 shares of Green Cross, while foreign investors and institutions have recorded net purchases of 97,792 shares and 116,752 shares, respectively.
※ Source: AI investment assistant AI Rassiro
※ This article was automatically generated in real time by a news generation algorithm jointly developed by Asia Economy and ThinkPool, a financial AI specialist company.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
